[ET Net News Agency, 26 January 2024] HSBC Global Research lowered its target price for
Sino Biopharm (01177) to HKD4.6 from HKD5 and maintained its "buy" rating.
The research house said it estimates innovative drugs sales will reach nearly RMB10bn in
2024 from around RMB7.8bn in 2023, implying over 25% growth y-o-y. (RC)